Therapeutics

Tools

Back to the Top
Search By Attributes

Search Results

Name Synonyms FDA Status Company Target Type Therapy Type Approved
For
Aducanumab BIIB037 Alzheimer's Disease (Phase 3) Biogen, Neurimmune Amyloid-Related Immunotherapy (passive)
BAN2401 mAb158 Alzheimer's Disease (Phase 3) Biogen, Eisai Co., Ltd. Amyloid-Related Immunotherapy (passive)
Gantenerumab RO4909832,
RG1450
Alzheimer's Disease (Phase 3) Chugai Pharmaceutical Co., Ltd., Hoffmann-La Roche Amyloid-Related Immunotherapy (passive)
Solanezumab LY2062430 Alzheimer's Disease (Phase 3) Eli Lilly & Co. Amyloid-Related Immunotherapy (passive) None